COYA · Healthcare
Coya Therapeutics Inc
13/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
17
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$113M
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqCM
About COYA THERAPEUTICS INC
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as…
Who's behind the signal
Every informed buyer we can see on COYA, across all three feeds.
Hedge funds · 3
Greenlight Capital (Einhorn)
Increased +172%
Point72 (Steve Cohen)
Decreased −39%
Citadel Advisors
Decreased −16%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
COYA THERAPEUTICS INC isn't in the top-10 model right now, but 3 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
3
Investors
0
New positions
1
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.3×
% of portfolio
0.5%
Position change
+172%
0.5% of Greenlight Capital's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−39%
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−16%
0.0% of Citadel Advisors's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to COYA THERAPEUTICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell COYA THERAPEUTICS INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订